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Abstract
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NETs) are a heterogenous group of tumours of various clinical pres-
entations. Proliferative activity of tumour cells is an essential parameter determining the course of the disease and affecting the prognosis. 
The Ki-67 antigen is an important marker of cell proliferation, which shows activity in all the phases of the cell cycle, excluding the G0 phase.
Aim of the study: To assess the expression of Ki-67 in GEP NETs and to examine the association of Ki-67 with the stage of the tumour 
(tumour size, presence of metastases) and the hormonal function of the tumour.
Material and methods: We included 61 patients with GEP NETs (25 males and 36 females aged between 20 and 82 years [mean age: 
56 years]). The proliferative activity was examined in paraffin blocks containing surgically removed tumour samples and in core-needle 
biopsies of primary and metastatic tumours. The presence of the Ki-67 antigen was assessed by immunohistochemistry using MIB-1 
monoclonal antibodies. Based on the Ki-67 proliferative index we determined the tumour grade. In addition, we determined the tumour 
stage according to the TNM classification. In all the subjects we determined the levels of the non-specific NET marker (chromogranin 
A) and of specific NET markers (serotonin, insulin and gastrin in the blood and 5-hydroxyindoleacetic acid [5-HIAA] in 24-hour urine).
Results: The diagnoses of low-grade (Ki-67 ≤ 2%), intermediate-grade (Ki-67 3–20%) and high-grade (Ki-67 > 20%) NET were established in 38, 12 and 
11 patients, respectively. Metastatic disease was diagnosed in 36/61 patients. A significantly higher expression of K-67 was observed in patients with 
metastatic disease (p = 0.01). A positive correlation was demonstrated between Ki-67 and the stage of the disease (p = 0.01) and between the histologic 
grade of the tumour and the stage of the disease (p = 0.01). No association between Ki-67 and the levels of chromogranin A, serotonin, insulin, gastrin 
and 5-HIAA was shown. There was also no difference in Ki-67 expression relative to the location of the primary tumour and the tumour size. 
Conclusions: The Ki-67 proliferative index is an essential parameter predicting the course of GEP-NETs. (Endokrynol Pol 2012; 63 (5): 362–366)
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Streszczenie
Wstęp: Nowotwory neuroendokrynne układu pokarmowego (GEP NETs, gastroenteropancreatic neuroendocrine tumors) stanowią hetero-
genną grupę nowotworów o różnym obrazie klinicznym. Istotnym parametrem decydującym o przebiegu choroby i wpływającym na 
jej rokowanie jest aktywność proliferacyjna komórek nowotworowych. Antygen Ki-67 jest ważnym markerem proliferacji komórkowej, 
wykazującym aktywność we wszystkich fazach cyklu komórkowego, z wyjątkiem fazy G0. 
Cel pracy: Celem pracy była ocena ekspresji antygenu Ki-67 w nowotworach neuroendokrynnych układu pokarmowego oraz badanie 
związku pomiędzy Ki-67 i stopniem zaawansowania choroby (wielkość guza, obecność przerzutów) oraz czynnością hormonalną guza.
Materiał i metody: Badaniem objęto 61 chorych z GEP NET (36 kobiet i 25 mężczyzn w wieku 20–82 lat, śr. wieku 56 lat). Do badania 
aktywności proliferacyjnej wykorzystano bloczki parafinowe, zawierające zmiany nowotworowe usunięte operacyjnie oraz materiał 
pobrany z ognisk pierwotnych i przerzutowych za pomocą biopsji gruboigłowej. Obecność antygenu Ki-67 oceniono za pomocą badania 
immunohistochemicznego z użyciem przeciwciał monoklonalnych MIB-1. W oparciu o wartość indeksu proliferacyjnego Ki67 ustalono 
stopień dojrzałości histologicznej nowotworu. Dodatkowo określono stopień zaawansowania nowotworu w oparciu o cechy TNM. 
U wszystkich chorych oznaczono stężenie niespecyficznego markera nowotworów neuroendokrynnych (chromogranina A) oraz specy-
ficznych markerów NETs (serotonina, insulina, gastryna we krwi oraz kwas 5-hydroksyindolooctowy w dobowej zbiórce moczu). 
Wyniki. U 38 chorych rozpoznano nowotwór neuroendokrynny o niskim stopniu złośliwości Ki-67 £ 2%, u 12 — o pośrednim Ki-67 
3–20%, u 11 — o wysokim stopniu złośliwości Ki-67 > 20%. Rozsianą chorobę nowotworową rozpoznano u 36/61 badanych. Stwierdzono 
znamiennie większą ekspresję antygenu Ki-67 w guzach neuroendokrynnych u chorych z przerzutami (p = 0,01). Wykazano dodatnią 
korelację pomiędzy Ki-67, a stopniem zawansowania choroby (staging) (p = 0,01) oraz dodatnią korelacją pomiędzy stopniem złośliwości 
histologicznej guza neuroendokrynnego a stopniem zaawansowania choroby (p = 0,01). Nie wykazano związku między Ki-67 a stężeniem 
chromograniany A, serotoniny, insuliny, gastryny i kwasu 5-hydroksyindolooctowego. Nie stwierdzono także różnicy w ekspresji antygenu 
Ki-67 w zależności od lokalizacji ogniska pierwotnego i wielkości guza neuroendokrynnego.
Wnioski: Wskaźnik aktywności proliferacyjnej Ki-67 jest istotnym parametrem pozwalającym przewidzieć przebieg nowotworów neu-
roendokrynnych układu pokarmowego. (Endokrynol Pol 2012; 63 (5): 362–366)
Słowa kluczowe: indeks proliferacyjny Ki-67, czynnik prognostyczny, nowotwory neuroendokrynne układu pokarmowego
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Introduction
Gastroenteropancreatic neuroendocrine tumours (GEP 
NETs) are a heterogenous group of tumours of diverse 
morphology, endocrine function, clinical course and re-
sponse to treatment. The latest WHO histopathological 
classification published in 2010 divides neuroendocrine 
tumours (NETs) into well differentiated and poorly dif-
ferentiated tumours [1]. The grade of the tumour is an 
essential factor determining the course of the disease 
and affecting the prognosis. It is an independent param-
eter whereby neuroendocrine tumours are divided into 
three prognostic groups: low grade (G1), intermediate 
grade (G2) and high grade (G3) tumours. Until recently 
the tumour grade was determined on the basis of mi-
totic index, which is the number of mitotic figures per 
10 high-power fields at 400 ¥ magnification. Mitotic 
index identifies proliferating cells only in the mitotic 
phase. For the past few years other methods have been 
investigated to assess the histological maturity of the tu-
mours, including the determination of the Ki-67 prolif-
erative index. This is an immunohistochemical method 
that assesses the expression of the nuclear antigen Ki-67 
using MIB-1 monoclonal antibodies. Ki-67 is an impor-
tant marker of cell proliferation which is active in cell 
cycle phases G1, S and G2 and during mitosis [2]. For this 
reason some authors consider this marker superior to 
mitotic index in the assessment of the proliferative activ-
ity of tumour cells [3]. In addition, the Ki-67 proliferative 
index is useful in the examination of tumour biopsies in 
which the amount of the tissue is too low to enable the 
grading of the tumour using mitotic index [1, 4]. Retro-
spective studies have demonstrated that Ki-67 shows 
a good correlation with tumour size, angioinvasion and 
behaviour of neuroendocrine tumours [5, 6].
Both the European Neuroendocrine Tumour Society 
(ENETS) and the World Health Organisation (WHO) 
have accepted mitotic index and Ki-67 as parameters to 
use in grading tumours [1]. Ki-67 has was also included 
in the Polish recommendations developed by the Polish 
Neuroendocrine Tumour Network in 2008 [7].
The aim of the study was to assess the expression 
of Ki-67 in GEP NETs and to examine the correlation of 
Ki-67 with the stage of the tumour (tumour size, pres-
ence of metastases) and with the hormonal function of 
the tumour.
Material and methods
The study population consisted of 61 patients with GEP 
NETs, including 25 males and 36 females aged between 
20 and 82 years (mean age: 56 years). Fasting blood 
samples for determination of hormones were collected 
at 8.00am from an arm vein. We determined the levels 
of the non-specific NET marker (chromogranin A) and 
of specific NET markers (serotonin, insulin and gastrin 
in the blood and 5-hydroxyindoleacetic acid [5-HIAA] 
in 24-hour urine).
The proliferative activity of the NETs was assessed in 
paraffin blocks containing surgically removed tumour 
samples and in core-needle biopsies of primary and 
metastatic tumours. The proliferative activity involving 
the determination of the Ki-67 antigen was assessed 
by immunohistochemistry using MIB-1 monoclonal 
antibodies. The percentage of cells containing Ki-67 
was calculated by examining 500–2000 tumour cells in 
a field demonstrating the most intensive nuclear stain-
ing (hot spot).
Grading and staging
In line with the most recent WHO classification pub-
lished in 2010 [1] we determined the grade of the NET 
based on the Ki-67 proliferative index (Table I) and the 
stage of the disease based on the TNM classification 
(tumour size, nodal involvement and the presence or 
absence of distant metastases).
Inclusion criteria
We included adults over the age of 18 years with a di-
agnosis of a GEP NET after obtaining written informed 
consent from each of the patients.
Exclusion criteria
Patients with GEP NETs who refused consent, minors, 
pregnant women, breastfeeding women, patients with 
end-stage liver disease, patients with stage 4 or 5 chronic 
kidney disease and patients with advanced heart failure 
were excluded from the study.
Ethical approval
The study was approved by the Bioethics Committee 
at the Silesian Medical University in Katowice, Poland 
(Resolution No KNW/0022/KB1/63/10).
Statistical analysis
All the statistical calculations were done using Med-
Calc. Linear regression curves were constructed for 
the observed correlations. The differences between 
the variables in the specific groups were assessed using 
univariate analysis of variance. Results with a p value 
below 0.05 were considered statistically significant.
Results
The most common locations of the primary tumour in 
the group of 61 patients with NETs were the pancreas 
(16 patients) and the large intestine (15 patients) (Table 
II). In 11 patients, the location of the primary tumour 
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could not be established and the diagnosis was based 
on the results of a core biopsy of a metastatic tumour in 
the liver. A total of 38 patients (62.3%) were diagnosed 
with low-grade NET (Ki-67 ≤ 2%) and 12 patients 
(19.7%) with intermediate-grade NET (Ki-67 3–20%). 
The remaining 11 patients (18.0%) had high-grade tu-
mours (Ki-67 > 20%). Metastatic disease was present in 
36 patients (59%), while no metastases were identified 
in 25 patients (Table III).
A significantly higher (p = 0.01) expression of Ki-67 
was identified in the tumours in patients with metastatic 
disease (Fig. 1). The mean Ki-67 proliferative index was 
5.4% in the group of patients without metastatic disease 
and 16.5% in the in the group of patients with metastatic 
disease. Using Spearman’s rank correlation we demon-
strated a positive correlation between the presence of 
metastases and the tumour grade (r = 0.44, p = 0.01). 
We also showed a significantly higher (p-0.024) rate of 
higher-grade NETs in the group of patients with meta-
static disease (Fig. 2). We found a positive correlation 
between Ki-67 and the stage of the disease (r = 0.31, 
p = 0.01) and a positive correlation between the grade of 
the NET and the stage of the disease (r = 0.32, p = 0.01).
We found no correlations between Ki-67 and the lev-
els of chromogranin A, insulin and gastrin in the blood 
and between Ki-67 and the level of 5-HIAA in 24-hour 
urine. We also found no difference in the expression 
of Ki-67 relative to the location of the primary tumour 
and the tumour size.
Discussion
For many years GEP NETs were treated as tumours of 
lower aggressiveness and a milder course (often of many 
years’ duration) compared to other neoplasms [8]. Most 
of these tumours were highly differentiated on histo-
pathologic examination. Further clinical observations 
revealed that some of the highly differentiated tumours 
were in fact characterised by a considerable aggressive-
ness: they invaded lymph nodes and internal organs 
and led to death in a relatively short time. For many 
years researchers looked for markers that would allow 
to predict the behaviour of NETs. Common acceptance 
Table I. Grading of GEP-NETs
Tabela I. Stopień histologicznej dojrzałości (grading) GEP 
-NET
Grade (G) Mitotic index Ki-67 
proliferative 
index (%)
G1 < 2 ≤ 2
G2 2–20 3–20
G3 > 20 > 20
Table II. Location of the primary tumour in the study 
population
Tabela II. Lokalizacja ogniska pierwotnego nowotworu 
neurendokrynnego w badanej grupie
Location of the primary tumour Number (%) of patients
Pancreas 16 (22.2%)
Stomach 7 (11.5%)
Small intestine 7 (11.5%)
Large intestine 15 (24.6%)
Appendix 7 (11.5%)
Unknown 9 (14.8%)
Total N = 61
Table III. Presence of metastases relative to the grade of the 
tumour
Tabela III. Obecność przerzutów w zależności od stopnia 
złośliwości GEP-NET
Grade Number (%)  
of patients 
N = 61
Number of patients 
without metastatic 
disease 
n = 25 (41%)
Number of patients 
with metastatic 
disease 
n = 36 (59%)
G1 38 (62.3%) 22 16
G2 12 (19.7%) 2 10
G3 11 (18.0%) 1 10
Figure 1. Correlation between the Ki-67 proliferative index and 
the presence of metastases in patients with GEP-NETs
Rycina 1. Średnia wartość wskaźnika Ki-67 w guzach 
neuroendokrynnych u chorych bez przerzutów i z przerzutami
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as such markers was gained by mitotic index and the 
presence of areas of necrosis in the tumour [9, 10] and, 
in the past few years, by the Ki-67 proliferative index 
[1, 5–7]. All these parameters define the histological 
maturity of the tumour (grade), which forms the basis 
for the division of NETs into three prognostic groups: 
low grade (G1), intermediate grade (G2) and high grade 
(G3) tumours [1, 11].
In our study we investigated the usefulness of the 
Ki-67 proliferative index for predicting the course of 
GEP-NETs. We mainly searched for an association be-
tween the tumour grade and the stage of the disease (in 
terms of tumour size and the presence of nodal involve-
ment and distant metastases). We also investigated the 
relationship between the proliferative activity of the 
tumour cells and the location of the tumour, tumour 
size and endocrine function. As expected, we observed 
a significantly higher expression of Ki-67 in the tumours 
of patients with metastatic disease (mean Ki-67: 5.5%). 
These findings are consisted with those of other authors 
[12, 13]. Among the 25 patients without metastatic dis-
ease 22 (88%) had a low grade (G1) tumour, 2 had an 
intermediate grade (G2) tumour and 1 had a high grade 
(G3) tumour. In the literature, there is still controversy 
as to the threshold values for Ki-67 that would separate 
tumours of low proliferative activity from those of high 
proliferative activity. In the ENETS and WHO classifi-
cations Ki-67 ranges of  ≤ 2%, 3–20% and > 20% were 
adopted to form the basis for the division of NETs into 
three degrees of histological maturity: G1 (highly dif-
ferentiated tumours of low proliferative activity and low 
grade), G2 (highly differentiated tumours of intermedi-
ate grade) and G3 (poorly differentiated tumours of high 
proliferative activity and aggressive clinical course) [1].
According to other authors, a Ki-67 value of 5% 
should be adopted as the threshold value that separates 
tumours of low proliferative activity from those of high 
proliferative activity and that determines a different 
response to chemotherapy. In a study published in 2008 
in which 180 non-functioning pancreatic NETs were 
investigated, Betting et al. showed prognostic value 
of Ki-67 proliferative index values exceeding 5% [14]. 
Better responses to systemic treatment in patients with 
NETs characterised by Ki-67 proliferative index values 
exceeding 5% have also been reported [15], which is 
why in this group of patients chemotherapy is recom-
mended as the treatment of choice. On the other hand, 
in GEP NETs with Ki-67 proliferative index values below 
5%, the response to systemic treatment is poor and in 
these patients other treatment modalities are preferred 
(somatostatin analogues, interferon alfa, angiogenesis 
inhibitors and mTOR inhibitors).
In our study, the mean Ki-67 in the group of patients 
with GEP NETs without metastases was 5.4%, which is 
consistent with the above studies. A notable finding of 
our study is the presence of multiple nodal and distant 
metastases in as many as 16 out of 38 (42%) patients 
with highly differentiated GEP NETs and a low Ki-67 
proliferative index of ≤ 2% (low grade [G1] tumours). 
When analysing our results one should take into ac-
count the heterogenous architecture of the tumours and 
the differences in the proliferative activity of the tumour 
cells between the primary tumour and the metastatic 
tumours. In some of the patients, the diagnosis was 
established on the basis of a core biopsy of a metastatic 
tumour, which may have limited the prognostic value of 
the Ki-67 proliferative index. There may be other factors 
that affect the course of the tumour independently of 
the proliferative activity of the tumour cells. Our find-
ings are consistent with other reports [16–21]. Of note 
is the fact that all the patients with metastatic disease 
who participated in our study were in a good clinical 
condition and showed no signs of progression.
Other findings in our study included a positive 
correlation between the grade of the tumour and the 
presence of metastases, a positive correlation between 
Ki-67 and the stage of the disease and a positive correla-
tion between the grade of the tumour and the stage of 
the disease, which supports the usefulness of the Ki-67 
proliferative index for predicting the behaviour of the 
tumour. These findings are consistent with those by 
other authors [22–24].
We showed no relationship between Ki-67 and the 
levels of chromogranin A, serotonin, insulin, gastrin 
Figure 2. A comparison of the grade of the NETs in the group of 
patients without metastatic disease and in the group of patients 
with metastatic disease
Rycina 2. Porównanie stopnia złośliwości histologicznej 
nowotworów neuroendokrynnych w grupie chorych z przerzutami 
i bez ognisk przerzutowych
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and 5-HIAA. We also found no relationship between 
the hormonal function of the tumour and the stage of 
the disease. According to some authors, the absence of 
hormonal function of GEP NETs is a poor prognostic 
factor, especially in pancreatic NETs, while other re-
searchers, us included, have found no differences in 
the course of GEP NETs between functioning and non-
functioning tumours [17]. We also found no difference 
in the expression of Ki-67 relative to the location of the 
primary tumour and the tumour size.
Conclusions
The Ki-67 proliferative index may be a helpful parameter 
in the prediction of the course of the disease in patients 
with GEP NETs. This parameter shows a correlation 
with the stage of the disease but no correlation with the 
levels of chromogranin A and other selected biochemical 
markers of NETs.
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